Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lafora's disease (EPM2)].

P Genton1

  • 1Centre Saint Paul - H. Gastaut, Marseille. piergen@aol.com

Revue Neurologique
|February 17, 2007
PubMed
Summary
This summary is machine-generated.

Lafora disease is a severe epilepsy causing progressive neurological decline. Diagnosis involves skin biopsy and genetic testing, with symptomatic treatment and supportive care crucial for management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic factors in epilepsy with eyelid myoclonia (Jeavons syndrome).

Revue neurologique·2023
Same author

Will MRI replace the EEG for the diagnosis of nonconvulsive status epilepticus, especially focal?

Revue neurologique·2021
Same author

Joseph Roger. 1918-2012.

Neurophysiologie clinique = Clinical neurophysiology·2014
Same author

Wicket spikes misinterpreted as focal abnormalities in idiopathic generalized epilepsy with prescription of carbamazepine leading to paradoxical aggravation.

Neurophysiologie clinique = Clinical neurophysiology·2009
Same author

[Epilepsy with absence status: A new syndrome of idiopathic generalized epilepsy].

Revue neurologique·2009
Same author

[Juvenile myoclonic epilepsy in a patient with history of infantile hemiplegia].

Revue neurologique·2008
Same journal

Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study.

Revue neurologique·2026
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
See all related articles

Area of Science:

  • Neurology
  • Genetics
  • Epilepsy

Context:

  • Lafora disease (LD) is a rare, severe, and progressive myoclonus epilepsy.
  • It typically manifests in adolescence with seizures, myoclonus, and cognitive deterioration.
  • LD exhibits genetic heterogeneity with mutations in EPM2A (laforin) and EPM2B (malin) genes.

Purpose:

  • To provide a comprehensive overview of Lafora disease, including its clinical presentation, genetic basis, diagnosis, and management.
  • To highlight the diagnostic criteria and challenges associated with genetic heterogeneity.
  • To emphasize the importance of symptomatic treatment and psychosocial support.

Summary:

  • Lafora disease presents with diverse seizure types, myoclonus, and rapid cognitive decline, often preceded by neurological symptoms.

Related Experiment Videos

  • Autosomal recessive inheritance is typical, with mutations in EPM2A and EPM2B accounting for most cases.
  • Diagnosis is supported by clinical findings, EEG, and axillary skin biopsy revealing Lafora bodies; genetic testing aids confirmation.
  • Treatment is symptomatic, focusing on seizure control, avoiding aggravating medications, and providing crucial psychological and social support.

    • Impact:

    • Improved understanding of Lafora disease's complex presentation and genetic underpinnings.
    • Enhanced diagnostic approaches through a combination of clinical, histological, and genetic methods.
    • Guidance for clinical management, emphasizing symptomatic treatment and supportive care for patients and families.
    • Foundation for future research into therapeutic strategies for this devastating neurological disorder.